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Abstract
Objective. To assess the decision-making process of patients
with vestibular schwannoma (VS).
Study Design. Patients with VS completed a voluntary survey
over a 3-month period.
Setting. Surveys were distributed online through email,
Facebook, and member website.
Subjects and Methods. All patients had a diagnosis of VS and
were members of the Acoustic Neuroma Association
(ANA). A total of 789 patients completed the online survey.
Results. Of the 789 participants, 474 (60%) cited physician
recommendation as a significant influential factor in deciding
treatment. In our sample, 629 (80%) saw multiple VS special-
ists and 410 (52%) sought second opinions within the same
specialty. Of those who received multiple consults, 242
(59%) of patients reported receiving different opinions
regarding treatment. Those undergoing observation spent
significantly less time with the physician (41 minutes) com-
pared to surgery (68 minutes) and radiation (60 minutes)
patients (P \ .001). A total of 32 (4%) patients stated the
physician alone made the decision for treatment, and 29
(4%) felt they did not understand all possible treatment
options before final decision was made. Of the 414 patients
who underwent surgery, 66 (16%) felt they were pressured
by the surgeon to choose surgical treatment.
Conclusion. Deciding on a proper VS treatment for patients
can be complicated and dependent on numerous clinical and
individual factors. It is clear that many patients find it important
to seek second opinions from other specialties. Moreover,
second opinions within the same specialty are common, and
the number of neurotologists consulted correlated with higher
decision satisfaction.
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V
estibular schwannoma (VS) is an uncommon benign
tumor with an annual incidence of 1.1 to 1.2 per
100,000 people and a mean age at presentation of 46
to 55 years.1-6 Recently, its diagnostic incidence has been on
the rise, the suspected consequence of increased frequency of
routine imaging among patients with headache or otologic
symptoms. Treatment for VS can be broadly categorized into
3 groups: observation, stereotactic radiation, and microsurgery.
Besides the presenting symptoms and its impact on quality of
life, the decision-making process among these VS treatment
options is oftentimes complex and multifaceted. These deci-
sions can be influenced by numerous clinical factors, includ-
ing but not limited to associated symptoms, tumor size,
growth rate, patient age, and general health or comorbid-
ities.1,2,7-12 Online resources provided by organizations
such as the Acoustic Neuroma Association (ANA) and
other VS support groups aim to assist patients in better
understanding all available treatment options and
approaches.13-15 In addition, second opinions from differ-
ent specialists at various treatment locations coupled with
insurance status may result in favoring one treatment
option over another.16-19 Other factors that may affect
decision making include the variation of beliefs and opi-
nions among physicians and family members, as well as
patient coping mechanisms and expectations.11,13,20,21
As a result, numerous factors motivate a patient’s treat-
ment decision given that each treatment presents with its
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own unique set of considerations. We aimed to evaluate the
various factors that play a role in the decision-making pro-
cess from the patients’ perspective. The utility of the study
is to ultimately provide physicians with insight into subjec-
tive patient opinions on the decision-making process to opti-
mize patient counseling and treatment experience.
Methods
With institutional review board approval from the University
of California, Irvine and in collaboration with the ANA, a vol-
untary and anonymous survey (Appendix 1, available in the
online version of the article) was made available over a 3-
month period spanning January to March 2017. Survey links
were posted on the ANA website, Facebook page, and emailed
to all members. Only patients diagnosed with VS were asked
to participate. A total of 789 participants completed the ques-
tionnaire. The survey assessed self-reported patient demo-
graphics, tumor characteristics, physician appointments,
information received, time delays, factors influencing the deci-
sion, and overall satisfaction with the decision. Patients in the
surgery group (SG) underwent either complete or partial resec-
tion. Patients in the radiation group (RG) received radiation
therapy or stereotactic radiosurgery. Patients in the observation
group (OG) underwent serial magnetic resonance imaging
(MRI) scans without radiation or surgery. The survey was
administered via RedCap (Nashville, Tennessee). Statistical
analysis was performed using PASW Statistics 18.0 software
(SPSS, Inc, an IBM Company, Chicago, Illinois) with a P
value of less than .05 considered statistically significant.
Results
Demographics, Treatment Modalities, and Tumor
Characteristics
Of the 797 questionnaires that were received, 789 were ana-
lyzed as complete surveys. The study sample was composed
of 65.4% females with key characteristics and treatment
modalities outlined in Table 1. The average interval
between time of diagnosis and survey participation was 7.18
years (range, 1 month to 45 years).
Important Decision-Making Factors
When asked about the most influential factor in deciding
treatment, physician recommendation (62.0%) was most
common, followed by quality-of-life concerns (54.5%),
tumor size (49.5%), symptoms at the time of diagnosis
(27.1%), complication risk (20.5%), dissatisfaction with
other treatment options (19.2%), information on the ANA
website (17.4%), and Internet research (12.7%).
When considering the number of neurotologists, neurosur-
geons, and radiation oncologists visited, 629 (79.7 %) of the
patients visited more than 1 specialist (mean, 3.1 specialists)
(Table 2). A total of 410 (52.0%) sought second opinions within
the same specialty (eg, visited 2 or more different neurotologists).
When seeking a second opinion, 40.7%, 24.3%, and 7.9% of the
patients visited more than 1 neurosurgeon, neurotologist, and
radiation oncologist, respectively (Supplemental Table S1, avail-
able in the online version of the article). Among those with multi-
ple consultations, 242 (38.5%) received different opinions
regarding treatment management. The primary determining factor
for decision making between discordant opinions was personal
choice in 139 (57.4%), concerns for treatment complications in
127 (52.5%), online research in 124 (51.2%), ANA information
or ANA member suggestions in 89 (36.8%), and concerns with
success rate in 62 (25.6%) of patients.
Decision Making: Time Delay between Diagnosis and
Decision
Only 5% of the survey responders made a decision of treat-
ment at the time of diagnosis. The average time from diagno-
sis to treatment decision was 97.6 days (median, 30 days).
On average, the SG took 63 days, RG 169.2 days, and OG
75 days before making their treatment decision. Of note, the
initial diagnosed tumor size negatively correlated (Pearson
correlation = –0.177) with time taken to decide on surgery
(P = .001). The most frequent reason for time delay between
diagnosis and treatment was seeking a second opinion in 306
(38%), scheduling in 176 (21.8%), and observation until
deciding active treatment in 124 (15.6%) of the patients.
Time Spent Discussing Treatment Options
The survey participants spent an average of 60.9 minutes dis-
cussing management options with their primary VS-treating
physician (range, 2 minutes to 6 hours). The SG spent 68.4
minutes (range, 2 minutes to 5 hours), RG 60.1 (range, 10
minutes to 6 hours), and OG 41.3 (range, 5 minutes to 4
hours). This time included multiple visits with these specialists.
The OG spent less time with their treating physician compared
Table 1. Vestibular Schwannoma Treatment Modalities and Respective Mean Age and Tumor Size at Diagnosis.
Treatment Participants, No. (%) Age, Mean (SD), y Tumor Size, Mean (SD), cm
Surgery 414 (52.5) 48.6 (11.3) 2.38 (1.33)
Radiation 224 (28.4) 55.6 (11.1) 1.72 (1.10)
Observation 121 (15.3) 57.2 (10.2) 1.12 (0.88)
Surgery 1 radiation 14 (1.8) 42.4 (13.0) 2.98 (1.31)
Undecided 16 (2.0) 56.9 (7.5) 1.70 (1.18)
Total 789 (100) 52.0 (11.8) 2.02 (1.28)
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other groups (P \ .001). Neurotologists, neurosurgeons, and
radiation oncologists spent an average of 63.7, 60.4, and 59.9
minutes with their patients, respectively.
Shared Decision Making and Change in Decision
In total, 55.5% (434) of the survey responders stated they
made the treatment decision on their own, 39.6% (316)
made it together with their physician, and 4% (32) stated
that the physician alone made the treatment decision. Of the
32 participants who stated the physician alone made the
decision, 21 (66%) underwent surgery and 11 (34%) under-
went radiation. Of the patients who made the decision alone
compared to those who made it with their physician, the
latter had a significantly larger tumor size at diagnosis
(mean, 1.80 cm vs 2.12 cm; P = .001) and took a signifi-
cantly shorter amount of time to make the decision (mean,
278.5 days alone vs 74.7 days with physician; P = .004).
Of the 417 patients with VS who underwent surgery, 66
(15.6%) specifically felt the surgeon pushed the surgery
option on them. Moreover, 29 (3.8%) of the survey respon-
ders did not feel informed or fully understand all possible
treatment options. In turn, 78.2% (594) of patients felt very
informed and understood all possible treatment options,
while 137 (18%) felt moderately informed. Last, 10.1% (79)
of the sample changed their final treatment decision after an
initial treatment decision was already made.
Satisfaction with Decision
In our sample, satisfaction with the ultimate treatment decision
did not differ between the SG and RG (P = .119), SG and OG
(P = .773), and RG and OG (P = .184). Also, there was no dif-
ference between active treatment (SG or RG) and observation
(OG; P = .471) with regard to satisfaction with the ultimate treat-
ment decision (Table 3). Bivariant Pearson correlation was con-
ducted to assess correlations between decision satisfaction and
tumor size, age at diagnosis, days taken to decide, minutes spent
with the primary VS treating physician, and number of specialists
seen. Only the number of neurotologists visited resulted in a sta-
tistical increase in satisfaction (P = .005; r2 = 0.011).
Discussion
We have demonstrated that the decision making of patients
with VS with regard to ultimate treatment is influenced by a
number of factors. This study evaluates the decision-making
process from the patients’ perspective, providing valuable
insight into the variables important in influencing patient
decisions and posttreatment satisfaction. The sample’s aver-
age age, tumor size, and treatment distribution are consistent
with data presented in the literature of large cohorts of
patients with VS, supporting the study validity.2,4,13,22
Physician Recommendation and Informed Consent
The data revealed that 60% of patients list physician recommen-
dation as one of the top 3 most influential factors when deter-
mining ultimate treatment options. Similarly, a study of British
patients with VS reported that their decision making was influ-
enced by their physicians in 80% of the participants.13,23 It has
been previously demonstrated that 41% of a sample of 739 sur-
veyed patients had unanswered questions due to inadequate
time with the physician.24 Others have reported that 32% to
69% of patients were not informed of other treatment options,
with 14% to 29% feeling pressured for a specific treatment.13,25
These data are consistent with our findings that 16% of the SG
felt the treatment had been pushed upon them, 4% of all
patients felt powerless in decision making, and 3.8% of the
survey responders were not informed about all the treatment
options. Although this occurred to a relative minority of
patients, its occurrence is noteworthy, given the importance of
physician recommendation. Interestingly, the average patient
spent 62 minutes with his or her treating physician, with the
increased time not resulting in higher patient satisfaction.
Secondary Consultation
It is not uncommon for patients to seek multiple consulta-
tions. A systematic review of oncology patients demonstrated
that 6.5% to 36% of patients sought second opinions.26
Although VS is unique due to the variety of comparable
treatment options, our study revealed that 80% of patients
visited more than 1 VS-treating specialist (defined as a neuro-
tologist, neurosurgeon, or radiation oncologist). Our sample
visited an average of 3 specialists overall, but at least 2 neu-
rosurgeons, neurotologists, and radiation oncologists were
seen by 40.4%, 24.3%, and 7.9% of patients, respectively. It
is thought that consulting multiple treating experts can either
validate previously discussed options or present discrepancy
in opinions. Tattersall and colleagues16 found in their institu-
tional study among general oncology patients that secondary
consultation resulted in 50% of patients receiving new infor-
mation and 40% of patients changing their treatment deci-
sion. Mellink et al27 found that 68% of oncology patients
seeking a second opinion obtained validation of previous rec-
ommendations, while 32% faced various levels of discre-
pancy. This is consistent with our sample, in which 30% of
patients received different opinions from specialties for treat-
ment recommendations. In light of this, physicians may help
facilitate treatment decisions by offering second opinions
through an open discussion with colleagues and specialists
both within and outside their own field to help ensure proper
and informed decision making on the patients’ behalf.
Table 2. Percentage of Each Treatment Group Visiting at Least 1
Neurosurgeon, Neurotologist, and Radiation Oncologist.
Seen at Least 1, %
Treatment
Group Neurosurgeon Neurotologist
Radiation
Oncologist
Surgery 90.3 81.9 24.4
Radiation 90.5 53.6 75.4
Observation 66.9 63.7 30.6
Total 85.9 69.4 40.6
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Role of Outside Resources
When facing discrepancies in recommendations by the treating
physician, 51% of patients sought information online, with 37%
benefiting from ANA’s information and virtual relationships
with members specifically. As a result, 29% of the sample
reported that ANA information or general Internet research
played a significant role in decision making. The utility of the
ANA and other informational and support groups has been pre-
viously well described, proving to be beneficial in providing
useful information that is communicated from patient to
patient.15,21 Despite the critical role these resources often play, a
physician’s endorsement of these communities that provide
valuable information at the expense of potential dissemination
of misinformation is largely unknown at this time.
Patient Satisfaction
Overall, 85% of the studied sample stated that they were
satisfied with their decision. This is despite evidence that
patients with VS have a lower quality-of-life (QoL) score
compared to patients with head and neck cancer.10,21 In
addition, no difference in decision satisfaction between SG,
RG, and OG was observed. This is in line with literature
demonstrating no change in QoL between the 3 treatment
groups.28-32 Interestingly, time taken to decide on treatment
or amount of time spent discussing treatment options with
the treating physician did not affect decision satisfaction.
Our results indicate that the number of different neurotolo-
gists visited, but not neurosurgeons or radiation oncologists,
correlates with a higher decision satisfaction of the survey
responders. However, the r2 of .011 suggests that a very
small portion of the variation in satisfaction is explained by
the number of neurotologists seen.
Limitations
As with any retrospective self-reporting study, the possibility
of recall bias as well as participation bias could play a sub-
stantial role in skewing data. Of significance, targeting ANA
members may represent a small and biased sample of the VS
population that are comfortable with technology and are able
to identify and obtain online support and resources when
making treatment decisions. In addition, expecting patients to
recall information and feelings regarding events that took
place from years prior may introduce a variety of inconsisten-
cies and issues. We attempted to overcome these limitations
by increasing the sample size of our study, yet these limita-
tions may be addressed with future prospective randomized
survey-based studies enrolling a less biased cohort.
Conclusion
With the continuing evolution and refinement of treatment
modalities, patient decision making in VS is influenced by
numerous factors. These include physician recommenda-
tion and the amount of time spent discussing treatment,
number and types of specialists visited, and online
resources. Considering that a small proportion of patients
with VS feel pressured into choosing a specific treatment
or do not feel informed about all possible options, seeking
second opinions and impartial discussion with the patients
may help better inform these patients and improve ultimate
satisfaction.
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Table 3. Patients Satisfaction Based on the Treatment.
Treatment
Extremely
Dissatisfied, No. (%)
Very Dissatisfied,
No. (%)
Satisfied,
No. (%)
Very Satisfied,
No. (%)
Extremely
Satisfied, No. (%) Mean (SD)
Surgery (n = 406) 10 (2.5) 25 (6.2) 117 (28.7) 108 (26.6) 146 (36.0) 3.87 (1.05)
Radiation (n = 215) 11 (5.1) 14 (6.5) 53 (24.7) 54 (25.1) 83 (38.6) 3.86 (1.16)
Observation (n = 103) 2 (1.9) 7 (6.8) 36 (35.0) 29 (28.2) 29 (28.2) 3.74 (1.01)
Total (N = 724) 23 (3.2) 46 (6.4) 206 (28.5) 191 (26.4) 249 (34.4) 3.83 (1.09)
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